VIR at a glance
Vir Biotechnology, Inc. (VIR, SEC CIK 1706431) filed its latest 10-K annual report on February 23, 2026, a 10-Q quarterly report on November 4, 2026, an 8-K current report on November 16, 2026 and Form 4 insider filings as recently as November 16, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Vir Biotechnology, Inc. (VIR) reported revenue of $68.6 million (down 7.6% from FY2024) and a net loss of $438.0 million. Diluted EPS was -$3.16.
- As of September 30, 2026, 29 institutional investment managers tracked by SignalX reported holding Vir Biotechnology, Inc. (VIR) shares worth $706.9 million in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by de Verneuil Vanina on November 3, 2026 of 2,407 shares at $11.10 per share.
- In the last 90 days, VIR insiders reported 0 open-market purchases ($0) and 2 open-market sales ($42K) on Form 4, a net sale of $42K.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $68.6M
- −7.6% vs prior year
- Insiders · 90 days
- 0 buys · 2 sells
- Net −$42K
- 13F holders
- 29 funds
- $706.9M · +0 vs prior quarter
- Latest 8-K
- Nov 16, 2026
- Item 1.01 · Item 8.01
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Dec 31, 2025
Business Overview
- Core business model focused on development and commercialization of infectious disease therapeutics
- New clinical programs highlighted: Phase 1 study of VIR-5525 and CHD ECLIPSE registrational program initiated with $125.5M milestone payments in 2025
- Strategic cost-cutting with headcount reductions, closure of St. Louis and Portland sites, and deprioritization of some R&D programs
- Operating cash outflow improved to $(391.8)M in 2025 from $(446.4)M in 2024, aided by $64.3M upfront from Norgine Agreement
- No off-balance sheet arrangements reported, maintaining transparent financial reporting standards
Risk Factors
- Regulatory risk from FDA revocation of sotrovimab EUA in Dec 2024, limiting near-term revenue generation from key product candidate
- Geopolitical risk due to patient enrollment challenges in clinical trials in countries affected by civil or political unrest
- Operational risk from restructuring initiatives completed by end of 2024 affecting cost structure and headcount reductions impacting R&D expenses
- Competitive risk from loss of GSK collaboration rights in March 2024, reducing revenue and profit-sharing opportunities
- Financial risk of potential dilution from up to $300M equity raise under Sales Agreement expiring Nov 2026, currently unutilized
Management Discussion & Analysis
- Revenue $114.8M for FY 2025, down from $129.4M in FY 2024, a 11.3% decrease
- Operating loss $354.7M in FY 2025 vs loss $348.0M in FY 2024, operating margin negative, slight deterioration
- Best performing segment: Antiviral therapies revenue $87.2M, down 8% YoY; worst: diagnostics $27.6M, down 18%
- Cash flow: Operating cash outflow $312.5M; capital allocation included $75M in share repurchases, $12M dividends, $45M capex
- Management outlook: Focus on pipeline advancement and cost control, risks from regulatory changes and competitive landscape
AI summary of the VIR 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Risk Factors
- New regulatory risk: FDA Fast Track designation for VIR-5500 in October 2026 may be revoked or fail to accelerate approval
- Competitive risk: FDA approval of the first U.S. CHD therapy in May 2026 could alter standards of care and physician adoption
- Financial risk: Cash, equivalents and investments of approximately $901.3 million fund operations for at least 12 months
- Clinical risk: Oncology trials may require dose or schedule modifications under FDA’s Project Optimus initiative
- Manufacturing risk: Limited third-party synthetic siRNA suppliers could cause raw-material shortages or delivery delays
Management Discussion & Analysis
- Quarterly revenue $(188) thousand vs $(428) thousand YoY, with nominal license and collaboration change
- Operating loss $(104.658) million vs $(173.443) million YoY, net loss $(96.252) million vs $(163.141) million
- Research and development expense $80.040 million vs $151.463 million, contract manufacturing $25.755 million vs $9.644 million
- Cash, cash equivalents and investments $901.3 million, restricted cash $8.8 million at September 30, 2026
- Operating cash outflow $115.141 million, financing inflow $242.533 million, including $162.2 million public offering proceeds
AI summary of the VIR 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 1.01: Entry into a Material Definitive Agreement
- $150 million common-stock offering: 15 million shares at $10.00 each
- Expected net proceeds $140.4 million, increasing to $161.5 million with full option exercise
Item 8.01: Other Events
- Proposed common stock offering announced on November 12, 2026, signaling potential equity financing and shareholder dilution
- Offering priced the same day, indicating the transaction advanced from proposal toward execution
Item EX-99.2: Item EX-99.2
- Public offering priced at $10.00 per share for 15,000,000 shares, raising expected gross proceeds of $150 million
- Underwriter option for 2,250,000 additional shares, creating further potential dilution and capital
Item EX-99.1: Item EX-99.1
- Vir Biotechnology announced a proposed underwritten public offering of common stock, creating potential shareholder dilution
- Underwriters may purchase up to 15% additional shares through a 30-day option
Item 7.01: Regulation FD Disclosure
- Vir scheduled a November 9, 2026 investor call to disclose topline Phase 3 ECLIPSE 1 results in chronic hepatitis delta
- ECLIPSE 1 evaluates monthly subcutaneous elebsiran plus tobevibart, potentially supporting Vir’s lead CHD combination strategy
Item 8.01: Other Events
- Phase 3 ECLIPSE 1 primary endpoint met: 44% achieved undetectable HDV RNA plus ALT normalization versus 0% delayed treatment, p<0.0001
- Key secondary endpoint: 79% achieved undetectable HDV RNA at Week 48 versus 0%, supporting broad antiviral efficacy
Item 2.02: Results of Operations and Financial Condition
- Q3 2026 financial results announced for quarter ended September 30, 2026
- Full results and management commentary available in Exhibit 99.1 accompanying the 8-K
Item EX-99.1: Item EX-99.1
- Q3 net loss $96.3M, or $0.57 per share, improved from $163.1M, or $1.17, largely due to the prior-year $75.0M milestone expense
- Cash, equivalents and investments $901.3M after a $106.5M quarterly decline, with operating runway projected into the second half of 2028
AI summaries of VIR 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for VIR
Don't miss the next VIR filing
- Alerts as it files. A push when VIR files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut VIR, by share count.
- Ask anything. An AI agent that reads every VIR filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Sawaf Aziz | A | Nov 15, 2026 | 75,000 | - |
| Sawaf Aziz | A | Nov 15, 2026 | 150,000 | - |
| Sabatini Brent | A | Nov 15, 2026 | 50,000 | - |
| de Verneuil Vanina | Sell | Nov 3, 2026 | 2,407 | $11.10 |
| de Verneuil Vanina | Sell | Nov 2, 2026 | 1,343 | $11.33 |
| Topalian Suzanne Louise | A | Oct 27, 2026 | 8,000 | - |
| Topalian Suzanne Louise | A | Oct 27, 2026 | 16,000 | - |
| Topalian Suzanne Louise | A | Oct 27, 2026 | 4,731 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $74.2M | $68.6M |
| Operating Income | - | -$587.2M | -$479.3M |
| Net Income | -$615.1M | -$522.0M | -$438.0M |
| Op. Margin | - | -791.3% | -699.2% |
| Net Margin | - | -703.4% | -638.9% |
| Balance Sheet | |||
| Total Assets | - | $1.4B | $1.0B |
| Equity | $1.6B | $1.2B | $765.3M |
| ROE | -38.7% | -45.4% | -57.2% |
| Per Share | |||
| EPS | $-4.59 | $-3.83 | $-3.16 |
| Cash Flow | |||
| Operating CF | - | -$446.4M | -$391.8M |
| CapEx | $21.6M | $7.3M | $4.8M |
Source: XBRL data in Vir Biotechnology, Inc. (VIR)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate VIR share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 29 | $706.9M |
| Q2 2026 | 29 | $700.3M |
| Q1 2026 | 30 | $557.2M |
| Q4 2025 | 28 | $320.6M |
| Q3 2025 | 29 | $307.4M |
| Q2 2025 | 29 | $277.5M |
| Q1 2025 | 26 | $222.9M |
| Q4 2024 | 21 | $199.0M |
- BlackRock+1.77M (+9%)
- Vanguard Portfolio Management LLC+529.1K (+5%)
- Dimensional Fund Advisors+197.5K (+6%)
- Invesco Ltd+63.4K (+13%)
- Vanguard Capital Management LLC+60.8K (+1%)
- State Street Corp−2.14M (-21%)
- Goldman Sachs Group−1.52M (-64%)
- Renaissance Technologies LLC−620.9K (-61%)
- Citadel Advisors LLC−588.8K (-59%)
- Morgan Stanley−440.8K (-20%)
- Franklin Resources+113.3K
- FMR LLC (Fidelity)−2.32M
Source: 13F-HR filings on SEC EDGAR (aggregated from 221 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
VIR filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Nov 16, 2026 | - | - | - |
| 8-K | Nov 16, 2026 | - | Analysis | - |
| 4 | Nov 16, 2026 | - | - | - |
| 8-K | Nov 9, 2026 | - | Analysis | - |
| 8-K | Nov 4, 2026 | - | Analysis | - |
| 4 | Nov 4, 2026 | - | - | - |
| 10-Q | Nov 4, 2026 | Sep 30, 2026 | Analysis | |
| 4 | Oct 28, 2026 | - | - | - |
| 8-K | Oct 28, 2026 | - | Analysis | - |
| 8-K | Oct 14, 2026 | - | Analysis | - |
| 8-K | Oct 8, 2026 | - | Analysis | - |
| 8-K | Oct 1, 2026 | - | Analysis | - |
| 4 | Aug 12, 2026 | - | - | - |
| SC 13G | Aug 7, 2026 | - | - | |
| 8-K | Aug 5, 2026 | - | Analysis | - |
| 10-Q | Aug 5, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Jul 24, 2026 | - | Analysis | - |
| 8-K | Jun 10, 2026 | - | Analysis | |
| 4 | Jun 10, 2026 | - | - | |
| 4 | Jun 2, 2026 | - | - | |
| 4 | Jun 2, 2026 | - | - | |
| 4 | May 28, 2026 | - | - | |
| 4 | May 28, 2026 | - | - | |
| 8-K | May 28, 2026 | - | Analysis | |
| 4 | May 28, 2026 | - | - |
Related Health Care companies
- FDMT · 4D Molecular Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- ADPT · Adaptive Biotechnologies CorpBiological Products, (No Diagnostic Substances)
- ADMA · ADMA BIOLOGICS, INC.Biological Products, (No Diagnostic Substances)
- ALEC · Alector, Inc.Biological Products, (No Diagnostic Substances)
- ALLO · Allogene Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- AMGN · AmgenBiological Products, (No Diagnostic Substances)
- AVXL · ANAVEX LIFE SCIENCES CORP.Biological Products, (No Diagnostic Substances)
- APGE · Apogee Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
VIR SEC filings: frequently asked questions
Are VIR insiders buying or selling?
In the last 90 days, Vir Biotechnology, Inc. (VIR) officers, directors and 10% owners reported no open-market purchases and 2 open-market sales worth $41,939 by 1 insider on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold VIR stock?
As of September 30, 2026, the largest Vir Biotechnology, Inc. (VIR) holders among the 13F filers tracked by SignalX were BlackRock ($251.0 million), Vanguard Portfolio Management LLC ($134.4 million), State Street Corp ($87.5 million), Vanguard Capital Management LLC ($72.1 million), Dimensional Fund Advisors ($37.1 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was VIR's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Vir Biotechnology, Inc. (VIR) reported revenue of $68.6 million (down 7.6% from FY2024) and a net loss of $438.0 million. Diluted EPS was -$3.16. The figures come from the XBRL data in the 10-K.
What are the main risks in VIR's latest 10-K?
In the 10-K filed February 23, 2026, Vir Biotechnology, Inc. (VIR) flagged: Regulatory risk from FDA revocation of sotrovimab EUA in Dec 2024, limiting near-term revenue generation from key product candidate. Geopolitical risk due to patient enrollment challenges in clinical trials in countries affected by civil or political unrest. (AI summary of the Risk Factors section.)
What did VIR report in its latest 8-K?
Vir Biotechnology, Inc. (VIR) filed an 8-K on November 16, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement) and Item 8.01 (Other Events). $150 million common-stock offering: 15 million shares at $10.00 each.
What are the latest VIR SEC filings?
Vir Biotechnology, Inc. (VIR) filed its latest 10-K annual report on February 23, 2026, a 10-Q quarterly report on November 4, 2026, an 8-K current report on November 16, 2026 and a Form 4 insider filing on November 16, 2026.
What is VIR's SEC CIK number?
Vir Biotechnology, Inc. (VIR)'s SEC Central Index Key (CIK) is 1706431. EDGAR lists every VIR filing under that number.
Ask anything about VIR
The research agent reads VIR's filings, financials, insider trades and 13F holders, then answers with sources.